Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Abraxane as Preoperative Therapy for Pancreatic Cancer
NCT01298011Phase 2Completed
- Sponsor
- Pancreatic Cancer Research Team
- Start
- May 2011
- Primary completion
- Dec 2013
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Pancreatic Cancer Research Team. Primary endpoint: Grade III/IV histological response in tumor specimen rate after induction therapy. Started May 2011; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01298011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298011.